Comparative Pharmacology
Head-to-head clinical analysis: TOPAMAX versus ZONISAMIDE.
Head-to-head clinical analysis: TOPAMAX versus ZONISAMIDE.
TOPAMAX vs ZONISAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antiepileptic; modulates voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
Anticonvulsant; blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and seizure propagation. Also weakly inhibits carbonic anhydrase.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg weekly to effective dose; usual maintenance dose 200-400 mg/day divided twice daily; maximum 1600 mg/day.
Oral, initial 100 mg daily, may increase by 100 mg every 2 weeks; maintenance 200-400 mg daily in 1-2 divided doses; maximum 600 mg daily.
None Documented
None Documented
Clinical Note
moderateZonisamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Fluconazole
Terminal elimination half-life is 21 hours (range 18-23 hours). Linear pharmacokinetics. Half-life is prolonged in renal impairment (CrCl <70 mL/min: ~35 hours).
Terminal half-life approximately 60-70 hours (range 50-80 hours) in adults; at steady state, half-life may be slightly longer. Clinical context: requires 2-3 weeks to achieve steady state.
Renal: ~70% (unchanged drug); remainder as metabolites. Biliary/fecal: minimal (<5%).
Renal: approximately 30% unchanged; remainder as glucuronide conjugate and reduced metabolite. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Zonisamide."